Repligen Announces CEO Transition Plan

Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors (“Board”) has approved the planned transition of Tony J. Hunt from Chief Executive Officer (“CEO”) to Executive Chair, effective September 1, 2024. The Company’s Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of Lead Independent Director.

Mr. Hunt has served as Chief Executive Officer and a member of the Company’s Board of Directors since May 2015, successfully leading the Company to innovation leadership in bioprocessing. Under his direction, the Company has enjoyed consistent above-industry growth through disciplined acquisitions (M&A), internal product development (R&D), commercial execution and operational excellence. During Mr. Hunt’s tenure as CEO, Repligen’s revenue grew from approximately $63 million in 2014 to $639 million in 2023, representing an average annual growth rate of over 30% over the nine-year period.

Karen A. Dawes, current Board Chair at Repligen, stated, “Over the past two years, the Repligen Board has developed a leadership succession plan to provide for the Company’s ongoing success. Elevating Tony Hunt to Executive Chair and promoting Olivier Loeillot to CEO ensures that we will continue to have a clear strategic vision and achieve our long-term goals. Tony has been an outstanding CEO and we thank him for his leadership and continued commitment to the Company. Olivier, given his exceptional experience and the positive impact he has made since joining Repligen, is an ideal successor to Tony. The Board is confident that he will build on our strong foundation and successfully lead Repligen through the next phase of growth.”